Latest Articles
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial Vanguard
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial The Clinical Trial Vanguard
Published: Aug. 1, 2026, 6:33 a.m.
Karyopharm To Stick With Blood Cancers As Xpovio Flops In Endometrial Cancer - insights.citeline.com
Karyopharm To Stick With Blood Cancers As Xpovio Flops In Endometrial Cancer insights.citeline.com
Published: July 31, 2026, 8:31 p.m.
Selinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer - Targeted Oncology
Selinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer Targeted Oncology
Published: July 31, 2026, 8:06 p.m.
'The whole room froze': IVF scan leads to shock cancer diagnosis - NZ Herald
'The whole room froze': IVF scan leads to shock cancer diagnosis NZ Herald
Published: July 31, 2026, 6:04 p.m.
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - OncLive
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer OncLive
Published: July 31, 2026, 5:22 p.m.
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - onclive.com
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer onclive.com
Published: July 31, 2026, 5:22 p.m.
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - CancerNetwork
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer CancerNetwork
Published: July 31, 2026, 2:37 p.m.
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - cancernetwork.com
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer cancernetwork.com
Published: July 31, 2026, 2:37 p.m.
Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis - Fierce Pharma
Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis Fierce Pharma
Published: July 31, 2026, 2 p.m.
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer - Endpoints News
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer Endpoints News
Published: July 31, 2026, 10:42 a.m.
Link copied to clipboard!